Edwards Lifesciences (MIL:1EW) Accounts Payable: €157 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1EW Edwards Lifesciences Corp MIL:1EW
72 GF Score
Price €80.78
GF Value €84.00
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Accounts Payable?

Edwards Lifesciences MIL:1EW 72 Accounts Payable is €157 Mil as of Mar. 2026. GuruFocus rates MIL:1EW with a GF Score™ of 72/100 and a GF Value™ of €84.00 (Fairly Valued). The stock has 5 warning signs investors should review.

Edwards Lifesciences's Accounts Payable for the quarter that ended in Mar. 2026 was €157 Mil.

Edwards Lifesciences's quarterly Accounts Payable increased from Sep. 2025 (€141 Mil) to Dec. 2025 (€194 Mil) but then declined from Dec. 2025 (€194 Mil) to Mar. 2026 (€157 Mil).

Edwards Lifesciences's annual Accounts Payable increased from Dec. 2023 (€171 Mil) to Dec. 2024 (€189 Mil) and increased from Dec. 2024 (€189 Mil) to Dec. 2025 (€194 Mil).

Edwards Lifesciences Accounts Payable Related Terms

Edwards Lifesciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Accounts Payable Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 180.98 190.59 171.11 188.52 194.29

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 159.47 140.54 140.58 194.29 156.65
MIL:1EW
72GF Score
Edwards Lifesciences Corp MIL:1EW
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €157 Mil mean?
Edwards Lifesciences (MIL:1EW) has a Accounts Payable of €157 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Accounts Payable too high?
Edwards Lifesciences' current Accounts Payable is €157 Mil. Overall, Edwards Lifesciences has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Accounts Payable compare to BSX and GEHC?
Edwards Lifesciences' Accounts Payable of €157 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Accounts Payable is €157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (MIL:1EW) is currently considered Fairly Valued. The stock's GF Value™ is €84.00, compared to a current price of €80.78 — trading 3.8% below its estimated fair value. The current Accounts Payable is €157 Mil. Edwards Lifesciences' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Edwards Lifesciences (MIL:1EW), the current Accounts Payable is €157 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (MIL:1EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of €80.78 is trading 3.8% below its estimated GF Value™ of €84.00. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for MIL:1EW:

  • Accounts Payable: €157 Mil
  • GF Value™: €84.00 vs. price of €80.78 (3.8% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the MIL:1EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
72GF Score

Get the complete analysis for MIL:1EW

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€80.78
Price
€84.00
GF Value